European Companies Search Engine
EU funding (€7,755,341): Crimean-Congo Haemorrhagic Fever Vaccine and Immunotherapy Hor1 Jan 2024 EU Research and Innovation programme "Horizon"
Text
Crimean-Congo Haemorrhagic Fever Vaccine and Immunotherapy
The CCHFVACIM project is an ambitious collaborative effort aimed at developing both prophylactic and therapeutic effective countermeasures against Crimean Congo Haemorrhagic Fever Virus (CCHFV), one of the most threatening vector-borne pathogens, widely distributed, including in the European continent. Deep structural biology studies on viral glycoproteins and investigation of the immunogenicity of the viral antigens will be combined with optimisation of an mRNA vaccine candidate against the virus and characterisation of the resulting protective immunity, as well as with the development of immunotherapeutic monoclonal antibodies (mAbs) based on CCHFVs antigenic targets. To achieve the overarching goals, the CCHFVACIM project will build on the success of previous projects such as CCHFever (FP7), CCHFVaccine (H2020) and go the extra mile by initiating a unique One-Health platform strategy to address different aspects of this severe public health threat. On one hand, the project will use several advanced animal models (mice, sheep, and non-human primate) to assess and compare the efficacy of mRNA vaccine candidates, mAbs and therapeutic mRNA; on the other hand, it will establish a biobank from CCHF patients to build up a pipeline for the production of mAbs against CCHFV from their B cells. Importantly, the project will also contribute to capacity building of European infrastructures, with the establishment of a platform on mRNA-based vaccine at one of the partner institutions. Ultimately, CCHFVACIM will permit to develop a road map to bring the most efficacious vaccine candidates and immunotherapy tools to clinical trial Phase I in humans. The project results will be widely disseminated among the scientific community, public health authorities, non-governmental organisations, outbreak management teams, and hospitals, with the final scope of both contributing to contain the burden of CCHF disease and increasing preparedness to new outbreaks.
Funded Companies:
| Company name | Funding amount |
| Department of Health | ? |
| European Research Infrastructure ON Highly Pathogenic Agents | €2,110,356 |
| Folkhalsomyndigheten | €1,593,300 |
| FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT | €1,110,963 |
| Institut National de la Sante et de la Recherche Medicale | €0.00 |
| Institut Pasteur | €400,000 |
| Institut Pasteur Du Cambodge | €428,750 |
| International Vaccine Institute | €185,304 |
| JUSTUS-LIEBIG-UNIVERSITAET GIESSEN | €387,500 |
| Karolinska Institutet | €444,500 |
| NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES | €97,500 |
| Sivas Cumhuriyet Universitesi | €195,750 |
| Statens Veterinaermedicinska Anstalt | €304,800 |
| THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Corp. | €496,619 |
Source: https://cordis.europa.eu/project/id/101137033
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Department of Health, Leeds.
The visualizations for "Department of Health - EU funding (€7,755,341): Crimean-Congo Haemorrhagic Fever Vaccine and Immunotherapy"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
